Endocrine and metabolic disorders

The Centers for Disease Control and Prevention (CDC) estimates that the prevalence of obesity in the U.S. has grown from 30.5% circa 2000 to 41.9% as of 2020. 

The United States has one of the highest rates of obesity in the world. Being overweight increases the risk of developing health problems, such as heart disease and certain forms of cancer. Obesity is also linked to an increased risk and severity of several autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and diabetes.  

Quotient Sciences' integrated approach to drug development, with a range of CRO and CDMO services, supports the development of new therapies to address endocrine and metabolic disorders. 

An experienced leader in early clinical development with proven experience conducting first-in-human healthy volunteer studies and initial patient proof-of-concept trials. 

Quotient Sciences performs trials with both healthy volunteers and patient cohorts in the same integrated, multi-part protocol—combining speed, flexibility, and scientific rigor into one, hybrid study that speeds up time to proof-of-concept.

We have a strong track record in recruiting and dosing special populations, such as healthy obese volunteers, from both our Miami, FL and Nottingham, UK clinical pharmacology units. 

In the last 2-3 years alone, we have completed multiple clinical trials in participants with high-BMI, exploring a range of endpoints, including pharmacokinetics, pharmacodynamics, metabolic markers, and body composition.

We're with you at every stage of drug product formulation and manufacturing for small molecules and peptides, applying scientific rigor and operational agility to help you overcome complex challenges.

We provide a complete solution to help advance your program at all stages:

• Formulation development
• Clinical drug product supply into Phase I-III patient trials
• Rapid scale-up to commercial drug product manufacturing

This includes experience with small molecules and peptides requiring a range of formulation approaches including solubility enhancement and modified-release. 

Learn more about our approach to modified-release dosage forms in our whitepaper, "Strategies for Accelerating the Development of Modified Release Oral Forms"

More patient-friendly methods to meet demand and administer GLP-1 therapies.

Innovations in peptide chemistry and drug delivery are enabling more peptides to be optimized for oral administration, making it easier for patients to start and continue treatment. 

Quotient Sciences have supported the development of oral peptide therapeutics, including GLP-1 agonists, with tailored formulation strategies and clinical protocols. 

Read more from our Chief Scientific Officer, Dr. Andrew Lewis, on how GLP-1 agonists work and the future of treating conditions beyond diabetes and obesity. 

Quotient Sciences pioneered the integration of CRO and CDMO solutions with Translational Pharmaceutics®—a disruptive platform proven to shorten development timelines by 12 months or more. 

Translational Pharmaceutics® merges operational efficiencies, scientific rigor, and clinical insights into a single program of work that is delivered under a single project manager and organization.

Close integration between drug product manufacturing and clinical testing enables better decision-making while reducing time and waste. This approach has been used on several high-profile drugs for obesity.